R-Squared Ventures
VC Fund
Los Altos, United States
R-Squared Ventures is a VC fund in Los Altos focused on Software and FinTech. R-Squared: “A model intended to predict future outcomes”. And the two Roy's behind it. We're an 'angel fund'. We're operators. Entrepreneurs, founders and CEOs that started, ran, scaled and sold start-up companies. Then as corporate executives post the acquisition. Invested as angels in over two dozen start-up companies.Passionate about supporting the companies and the founders we're backing. R-Squared Ventures was founded as an extension to our personal investments. Now backed by over three dozen top entrepreneurs, founders, CEOs and investors that are our LPs - in Silicon Valley and Israel - that want to be part of our investments and extend their experience, network and support to our companies. We're excited about backing strong founders - with the drive, passion and ability to execute on a real problem, in a sizable market, with a big vision, and a defensible solution and path to succeed. Mainly focused on Fintech, Enterprise/SMB SaaS, Marketplaces and Digital Commerce. Though we also invested in other categories, such as B2C companies, Gaming, AgTech, and others.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries R-Squared Ventures invests in
Stages R-Squared Ventures invests in
Countries R-Squared Ventures invests in
Round sizes
Contacts
3 more contacts available
Round size
- Seed
- $2.4M–$11M
- Series A
- $13M–$1B
Investment Focus
Industry
- Software 12 (44%)
- FinTech 4 (15%)
- Artificial Intelligence 4 (15%)
- Finance 3 (11%)
- E-Commerce 3 (11%)
Stage
- Seed 14 (52%)
- Series A 5 (19%)
- Funding Round 3 (11%)
- Series B 2 (7%)
- Pre-Seed 1 (4%)
Country
- United States 14 (52%)
- Israel 6 (22%)
- India 2 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Roy Erez
Founding Partner
|
Founding Partner | Total investments: 1 | Find email | |
Roy Rubin
Founding Partner
|
Founding Partner | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nimble Way
|
Nimble Way optimizes data collection pipelines for continuous, stable, accurate public web data capture by using IP infrastructure and external data platforms. They provide data gathering services to company needs. The people contact through phone number, email, and application form. | $47M / Series B / Feb 24, 2026 | |
Quantum Elements
|
Quantum Elements Platform Build, optimize, and launch quantum applications faster than ever. | Seed / Feb 18, 2026 | |
Slice Global
|
Issue equity to your teams in any country, stay in compliance locally, protect your employees from tax penalties, easily & quickly. | $25M / Series A / Jan 28, 2026 | |
Panjaya
|
Panjaya offers generative-AI dubbing technology to localize any video content. The company's AI replicates original content in a variety of languages with engaging results. Video content creators from a variety of industries can easily and accurately recreate videos that appeal to a global audience using Panjaya. | $9.5M / Nov 08, 2024 | |
Xaira Therapeutics
|
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area. | $1B / Apr 23, 2024 | |
|
Xaira Therapeutics
|
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area. | $1B / Series A / Apr 23, 2024 | |
Alysio
|
Alysio is the People Performance Management Platform for your sales organization. | $3.3M / Seed / Apr 15, 2024 | |
Clearitty
|
Clearitty - The Ultimate Sales Accelerator by Turning Deal Insights into Revenue We provide the tools and insights for sales executives to close deals faster and outperform competitors, empowering you to drive growth and success. It’s free to start — no trial, no contract, no risk.Clearitty was born out of a shared frustration experienced bysales executives and entrepreneurs alike – the lack of critical insights about new buyers. These invaluable insights are often held by those who have successfully navigated the sales process with these coveted clients.Recognizing the gap, in 2022 we created Clearitty, dedicated to developing an intelligence tool that helps sales executives shorten sales cycles and close deals more efficiently.Our goal is to build the world’s largest database of buyer insights, empowering sales executives with the knowledge they need to succeed. | Pre-Seed / Mar 01, 2024 | |
|
Slice Global
|
Issue equity to your teams in any country, stay in compliance locally, protect your employees from tax penalties, easily & quickly. | $7M / Seed / Feb 28, 2024 | |
SiPhox Health
|
SiPhox offers a handheld testing device with RNA/DNA and protein testing for point-of-care and At-Home solutions. The company's kit is made by multiplexing RNA, antibody, and antigen tests on a single silicon photonic chip which is amplified by plasmon resonance and silicon photonic resonator readout, enabling users to undertake tests fordisease safely and in a disposable point-of-care and at-home manner.SiPhox was founded in 2020 and is based in Cambridge, Massachusetts, USA. | $10M / Seed / Jul 19, 2023 | |
| See all 27 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does R-Squared Ventures invest in?
R-Squared Ventures invests primarily in Software, FinTech and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is R-Squared Ventures's check size?
R-Squared Ventures typically joins rounds of $2.4M–$11M at Seed and $13M–$1B at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds R-Squared Ventures participates in.
How do I contact R-Squared Ventures?
Public channels for R-Squared Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at R-Squared Ventures?
The team at R-Squared Ventures includes Roy Erez (Founding Partner) and Roy Rubin (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
